Daojun Lv
Impact in
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Molecular Biology top 10%
- Circular RNAs in diseases
- RNA modifications and cancer
- RNA Research and Splicing
- Epigenetics and DNA Methylation
Papers in
-
- Circular RNAs in diseases 12
- RNA modifications and cancer 6
- RNA Research and Splicing 5
-
- Prostate Cancer Treatment and Research 9
- Ferroptosis and cancer prognosis 9
- Co-authors
- Fangpeng Shu (17 shared papers)Shan‐Chao Zhao (11 shared papers)Yu‐Zhong Yu (9 shared papers)Chong Wang (7 shared papers)Xian‐Lu Song (8 shared papers)Xumin Zhou (10 shared papers)Kaihui Wu (5 shared papers)Xiangming Mao (6 shared papers)
- Journals
- Frontiers in Cell and Developmental Biology (4 papers)Oncotarget (3 papers)Frontiers in Immunology (2 papers)Annals of Oncology (2 papers)PeerJ (2 papers)
- Partner nations
- ChinaUnited StatesTaiwan
In The Last Decade
Daojun Lv
52 papers receiving 1.3k citations
Hit Papers
Peers
Comparison fields: 5 of 102
- Cancer Research 630
- Molecular Biology 915
- Pulmonary and Respiratory Medicine 253
- Aging 11
- Oncology 165
Countries citing papers authored by Daojun Lv
This map shows the geographic impact of Daojun Lv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daojun Lv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daojun Lv more than expected).
Fields of papers citing papers by Daojun Lv
This network shows the impact of papers produced by Daojun Lv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daojun Lv. The network helps show where Daojun Lv may publish in the future.
Co-authors
The 25 scholars most cited alongside Daojun Lv, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 55 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 162 | |
| 2 | Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis Hit paper breakdown → | 2022 | 132 |
| 3 | 2022 | 108 | |
| 4 | 2018 | 88 | |
| 5 | 2022 | 68 | |
| 6 | 2019 | 57 | |
| 7 | 2020 | 47 | |
| 8 | 2021 | 41 | |
| 9 | 2023 | 40 | |
| 10 | 2021 | 40 | |
| 11 | 2017 | 34 | |
| 12 | 2022 | 33 | |
| 13 | 2021 | 33 | |
| 14 | 2017 | 31 | |
| 15 | 2016 | 28 | |
| 16 | Expression of PGAM1 in renal clear cell carcinoma and its clinical significance. | 2015 | 27 |
| 17 | 2019 | 24 | |
| 18 | 2018 | 24 | |
| 19 | 2024 | 23 | |
| 20 | 2021 | 22 |
About Daojun Lv
Daojun Lv is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research, Oncology and Surgery, having authored 55 papers that have together received 1.3k indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (13 papers), Circular RNAs in diseases (12 papers), Prostate Cancer Treatment and Research (9 papers), MicroRNA in disease regulation (9 papers), Ferroptosis and cancer prognosis (9 papers), Cancer Immunotherapy and Biomarkers (7 papers), RNA modifications and cancer (6 papers) and RNA Research and Splicing (5 papers). The work is most often cited by research in Cancer Research (630 citations), Molecular Biology (915 citations), Pulmonary and Respiratory Medicine (253 citations), Aging (11 citations) and Oncology (165 citations). Daojun Lv has collaborated with scholars based in China, United States and Taiwan. Frequent co-authors include Fangpeng Shu, Shan‐Chao Zhao, Yu‐Zhong Yu, Chong Wang, Xian‐Lu Song, Xumin Zhou, Kaihui Wu, Xiangming Mao, Bin Lei and Xiangkun Wu. Their work appears in journals such as Frontiers in Cell and Developmental Biology, Oncotarget, Frontiers in Immunology, Annals of Oncology and PeerJ.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.